Immix Biopharma reports Q3 net loss of USD 13.9 million

• Immix Biopharma reported a third-quarter 2026 net loss of $13.9 million and operating expenses of $15.9 million.
• Cash, cash equivalents and marketable securities rose 46% from June 30 to $340.9 million at September 30, 2026.
• The cash, cash equivalents and marketable securities balance is expected to provide operating runway into mid-2028.
• NXC-201 achieved an 89% complete response rate across 45 patients in the NEXICART-2 trial.
• A BLA submission is planned for mid-2027, with the NEXICART-3 frontline trial expected to begin in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-051402), on November 12, 2026, and is solely responsible for the information contained therein.